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Abstract
Background: Mitral annulus calcification (MAC) has been associated with cardiovascular diseases, 
including heart failure (HF); however, the associations between MAC and both the category and etiology 
of HF have not been fully elucidated. The aim of this study was to investigate the relationship between 
MAC and three types of HF rehospitalization: HF with preserved ejection fraction (HFpEF), HF with 
mid-range EF (HFmrEF), and HF with reduced EF (HFrEF).
Methods: We enrolled consecutive patients undergoing echocardiography, who were admitted to our 
hospital for clinically indicated congestive HF between April 2014 and March 2018. Cox proportional-
hazards models were used after adjusting for age, gender, and hypertension.
Results: Of 353 patients, 40 (11.3%) had MAC. With a median follow-up of 2.8 years, 100 (28%) 
patients were rehospitalized for congestive HF (HFpEF 40%, HFmrEF 16%, HFrEF 44%, respectively). 
According to the Kaplan-Meier method, the estimated incidence of HFpEF rehospitalization in the MAC 
group was significantly greater than that in the non-MAC group (p < 0.001) whereas the incidences of 
HFmrEF and HFrEF rehospitalization were comparable between the groups (p = 0.101 and p = 0.291,  
respectively). In a multivariate analysis, MAC remained significantly associated with HFpEF rehospi-
talization (hazard ratio: 3.379; 95% confidence interval: 1.651–6.597). At initial HF hospitalization, 
E/e’ was significantly higher in the MAC group (both septum and lateral, p < 0.05), suggesting a pos-
sible relationship between MAC and left ventricular diastolic function.
Conclusions: Mitral annulus calcification was associated with increased HFpEF rehospitalization 
and might be a cause of left ventricular diastolic dysfunction. (Cardiol J)
Key words: mitral annulus calcification, heart failure, heart failure with preserved  
ejection fraction
Introduction
Mitral annulus calcification (MAC) is a chron-
ic degenerative process in the fibrous support 
structure of the mitral valve [1–3]. MAC is often 
observed in elderly patients with atherosclerotic 
disease, and its prevalence increases with aging, 
multiple cardiovascular risk factors, and chronic 
kidney disease (CKD) [2–5]. MAC has been associ-
ated with increased cardiovascular disease (CVD) 
including congestive heart failure (HF), mitral 
valve disease, arrhythmias, stroke, and mortality 
[3, 6–11].
Heart failure commonly occurs as a result of 
several CVDs, leading to cardiovascular death. Re-
cently, HF has been divided into three groups based 
on the left ventricular ejection fraction (LVEF): HF 
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with mid-range LVEF (HFmrEF, LVEF 40–49%), 
and HF with reduced LVEF (HFrEF, LVEF < 40%) 
[12]. Each HF phenotype is associated with differ-
ent clinical outcome, characteristics, etiology, and 
required management. HFpEF patients are older, 
more often women, more likely to have hyperten-
sion, and less likely to have coronary artery disease 
(CAD), compared to HFrEF patients. HFmrEF 
patients show intermediate characteristics [13–15]. 
In addition, the incidence of HF rehospitalization 
in HFpEF patients is lower than that in HFrEF 
patients, and HFmrEF is intermediate between the 
other two groups. Therefore, it is considered that 
the HFmrEF phenotype represents a transitional 
status or overlap between HFpEF and HFrEF.
While previous studies have shown that MAC 
is a cause of HF, the association of MAC with the 
category and etiology of HF has not been fully 
elucidated. The aim of this study was to investigate 




This study is a retrospective observational co-
hort. We enrolled 456 consecutive patients under-
going transthoracic echocardiography (TTE), who 
were admitted to Fukuoka University Hospital for 
clinically indicated congestive HF between April 
2014 and March 2018. The diagnosis of HF was 
made by the attending cardiologists in our hospi-
tal based on the criteria of the Framingham study 
[16]. We divided the patients into MAC and non-
-MAC groups at baseline. The primary endpoints 
were the incidence of HF rehospitalization and 
their subtypes (i.e. HFpEF, HFmrEF, and HFrEF) 
at the follow-up date. Secondary endpoints were 
myocardial infarction (MI), cardiovascular death, 
and all-cause death. TTE was performed twice: on 
admission for the initial HF and at rehospitalization 
due to HF, with a commercially available system 
(Vivid E9, GE Healthcare, Milwaukee, WI, USA; or 
EPIQ 7G, Philips Medical Systems, Andover, MA, 
USA). Selection to the MAC or non-MAC group 
was determined by TTE at the initial HF hospi-
talization, and subtypes of HF rehospitalization 
were divided into three groups according to TTE-
-derived LVEF at the HF rehospitalization. Cases of 
HF rehospitalization due to ischemic heart disease 
(IHD, n = 8), valvular heart disease (VHD, n = 58), 
or post valvular surgery (n = 37) were excluded. 
HF rehospitalization due to IHD was defined as 
CAD requiring revascularization on admission (i.e. 
acute coronary syndrome), and VHD was defined 
as moderate to severe aortic and/or mitral valve 
disease at each TTE. Ultimately, we included 353 
patients and performed further analysis.
All data were retrospectively collected at the 
initial HF hospitalization and rehospitalization, and 
analyzed using the database of Fukuoka University 
Hospital. The study was performed according to 
the Declaration of Helsinki regarding investiga-
tions in humans and approved by the ethics com-
mittee of Fukuoka University Hospital (EC/IRB: 
U19-12-002). Informed consent was obtained in 
the form of an opt-out on a website.
MAC assessed by TTE
Mitral annulus calcification was defined as 
the presence of bright echo density located at the 
junction of the atrioventricular groove and poste-
rior mitral leaflet on M-mode or two-dimensional 
imaging in parasternal or apical windows. The 
severity of MAC was defined as previously de-
scribed [3, 17]: mild (focal, limited increasing echo 
density of the mitral annulus), moderate (marked 
echo density involving one-third to one-half of 
the mitral ring circumference), or severe (marked 
echo density involving more than one-half of the 
circumference of the mitral ring or with intrusion 
into the left ventricular [LV] inflow tract, or maxi-
mal MAC thickness measured from the anterior to 
the posterior edge at its greatest width > 4 mm) 
determined in a parasternal short-axis view at the 
level of the mitral annulus. In the present study, we 
identified the presence of MAC as MAC of greater 
than moderate severity (Fig. 1). The presence and 
severity of MAC were collected by 2 investigators 
who were blinded to clinical information about the 
subjects. Patients with MAC of greater than moder-
ate severity by both investigators were considered 
to be the MAC group.
Statistical analysis
Values are expressed as mean ± standard 
deviation if the variable was normally distributed, 
or median (interquartile range) if not. The Shapiro-
-Wilk test was used to assess whether data were 
normally distributed or not. A two-tailed p < 0.05 
was considered statistically significant. Patients 
were divided into two groups according to the 
presence of MAC. Groups were compared using 
Student’s t-test or the Wilcoxon test for continu-
ous values, and the chi-squared test was used for 
categorical data, as appropriate. Kaplan-Meier 
estimates were used to evaluate the association 
of MAC with HF rehospitalization, MI, cardio-
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vascular death, and all-cause death. Above all, 
HF rehospitalization was studied according to the 
three subtypes defined by LVEF. Cox proportional 
hazards regression models were used to assess the 
relationship between baseline clinical characteris-
tics, including MAC and HFpEF rehospitalization. 
In multivariate Cox proportional hazard regression 
analyses, MAC was adjusted for the following 
baseline variables by each model: model 1, adjusted 
for age, gender, and hypertension, which are tradi-
tional HFpEF risk factors [13–15]; models 2 and 3, 
adjusted for covariates that were significant in 
a univariate analysis. All statistical analyses were 




Of the 353 patients who met the inclusion 
criteria, 40 (11.3%) had MAC. The baseline clini-
cal characteristics and echocardiographic meas-
urements are shown in Table 1. At the baseline 
examination, patients with MAC were significantly 
older and had a lower frequency of smoking and 
a smaller body surface area (BSA) compared to 
those without MAC. There were no significant dif-
ferences between groups with respect to gender, 
prevalence of hypertension and atrial fibrillation, 
or laboratory values, including B-type natriuretic 
peptide, creatinine, and hemoglobin.
Among TTE variables, LVEF, E-wave velocity 
(transmitral Doppler flow pattern; TMF), and E/e’ 
septum and lateral (tissue Doppler image; TDI) 
were significantly higher in the MAC group. While 
the LV end-systolic dimension was significantly 
smaller and the LV end-diastolic dimension tended 
to be smaller in the MAC group, there were no 
significant differences in the indexed LV end-
-systolic dimension (LV end-systolic dimension/ 
/BSA), indexed LV end-diastolic dimension (LV 
end-diastolic dimension/BSA), left atrial (LA) di-
ameter, LA volume index, A wave velocity (TMF), 
e’ septum (TDI), or e’ lateral (TDI) between the 
groups.
Outcomes
During a median follow-up of 2.8 years, there 
were 100 (28%) HF rehospitalizations, 4 (1%) 
MIs, 30 (9%) cardiovascular deaths, and 49 (14%) 
all-cause deaths. Of the 100 HF rehospitalizations, 
40 were HFpEF, 16 were HFmrEF, and 44 were 
HFrEF. The incidence of HF rehospitalization, 
especially HFpEF rehospitalization, was signifi-
cantly higher and cardiovascular death tended to 
be more prevalent in subjects with MAC than in 
those without MAC (Table 2).
Figure 1. Representative case of mitral annulus calcifi-
cation.
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Figure 2 shows Kaplan-Meier survival curves 
for HF rehospitalization. The incidence of HF 
rehospitalization in patients with MAC was signifi-
cantly higher (log-rank, p = 0.004). The incidence 
of HFpEF rehospitalization was significantly higher 
and that of HFmrEF rehospitalization tended to be 
higher in patients with MAC (log-rank, p < 0.001; 
p = 0.101, respectively), whereas the incidence 
of HFrEF hospitalization tended to be lower in 
the MAC group (log-rank, p = 0.291). Figure 3 
Table 1. Baseline clinical characteristics and echocardiographic measurements.
Non-MAC (n = 313) MAC (n = 40) P
Age [years] 75 (65–83) 82 (75–88) < 0.001
Male 210 (67%) 21 (53%) 0.073
Hospital days 17 (12–22) 17 (10–22) 0.733
NYHA: 0.933
II 94 (30%) 13 (33%)
III 93 (30%) 12 (30%)
IV 126 (40%) 15 (37%)
Ischemic heart disease 118 (38%) 18 (45%) 0.375
Smoking 176 (56%) 15 (38%) 0.025
Hypertension 199 (64%) 25 (63%) 0.894
Diabetes mellitus 133 (42%) 11 (28%) 0.063
Atrial fibrillation 127 (41%) 20 (50%) 0.258
Medication at discharge:
ACE-I or ARB 229 (73%) 24 (60%) 0.091
Beta-blocker 237 (76%) 28 (70%) 0.439
Diuretics 271 (87%) 34 (85%) 0.786
Body mass index [kg/m2] 23.0 (20.8–26.6) 21.6 (19.3–25.3) 0.054
Body surface area [m2] 1.62 (1.49–1.77) 1.48 (1.35–1.67) 0.001
Laboratory data:
BNP [pg/mL] 579 (327–1024) 701 (332–1105) 0.306
Creatinine [mg/dL] 1.11 (0.84–1.66) 1.17 (0.91–1.47) 0.961
Hemoglobin [g/dL] 12.2 ± 2.4 11.4 ± 2.2 0.069
TTE, baseline:
LVEF [%] 40.2 (28.3–53.3) 52.4 (38.4–61.9) 0.002
LVDd [mm] 52.4 ± 9.7 49.2 ± 8.5 0.053
Indexed LVDd [mm/m2] 32.2 ± 6.0 32.9 ± 6.2 0.523
LVDs [mm] 41.6 (33.2–49.7) 34.0 (29.3–42.5) 0.001
Indexed LVDs [mm/m2] 25.7 (20.1–30.6) 22.6 (19.2–28.5) 0.101
LA diameter [mm] 43.9 (39.2–49.1) 45.7 (40.8–53.0) 0.166
LA volume index [mL/m2] 44.9 (33.1–61.1) 51.6 (38.2–76.1) 0.189
E wave velocity (TMF) [cm/s] 72.1 (52.6–96.6) 80.9 (63.8–115.2) 0.019
A wave velocity (TMF) [cm/s] 67.1 (48.5–88.7) 69.9 (38.3–110.7) 0.635
e’ septum (TDI) [cm/s] 4.7 (3.7–6.0) 4.4 (3.0–6.2) 0.551
e’ lateral (TDI) [cm/s] 6.1 (4.5–8.4) 6.1 (4.6–7.5) 1.000
E/e’ septum 15.4 (11.4–20.5) 20.5 (15.6–22.9) 0.017
E/e’ lateral 11.8 (7.9–17.4) 14.9 (11.8–17.1) 0.039 
Data are presented as mean ± standard deviation or median (interquartile range) for continuous variables or the number (percent) of patients 
for category variables. ACE-I — angiotensin converting enzyme inhibitor; ARB — angiotensin II receptor blocker; BNP — B-type natriuretic 
peptide; Indexed LVDd — LVDd/body surface area; Indexed LVDs — LVDs/body surface area; LA — left atrium; LVDd — left ventricular end-
-diastolic dimension; LVDs — left ventricular end-systolic dimension; LVEF — left ventricular ejection fraction; MAC — mitral annulus calcifica-
tion; NYHA — New York Heart Association functional classification; TDI — tissue Doppler image; TMF — transmitral Doppler flow pattern; 
TTE — transthoracic echocardiography
4 www.cardiologyjournal.org
Cardiology Journal
Table 2. Association with mitral annulus calcification (MAC) and clinical outcome.
Non-MAC (n = 313) MAC (n = 40) P
All-cause death 41 (13%) 8 (20%) 0.256
Cardiovascular death 23 (7%) 7 (18%) 0.050
Myocardial infarction 4 (1%) 0 (0%) 0.325
Heart failure rehospitalization 80 (26%) 20 (50%) 0.002
Heart failure subtype: 0.008
HFpEF 27 (34%) 13 (65%)
HFmrEF 12 (15%) 4 (20%)
HFrEF 41 (51%) 3 (15%)
HFpEF — heart failure with preserved ejection fraction; HFmrEF — heart failure with mid-range ejection fraction; HFrEF — heart failure with 
reduced ejection fraction
Figure 2. Kaplan-Meier estimates for the primary endpoint according to the presence or absence of mitral annulus 
calcification (MAC); A. Heart failure rehospitalization; B. Heart failure with preserved ejection fraction (HFpEF) rehos-
pitalization; C. Heart failure with mid-range ejection fraction (HFmrEF) rehospitalization; D. Heart failure with reduced 































































Follow up (days) Follow up (days)
Follow up (days)
Log-rank p = 0.004
Log-rank p = 0.101 Log-rank p = 0.291





































































Yuta Kato et al., MAC and HF rehospitalization subtypes
shows Kaplan-Meier survival curves for MI, car-
diovascular death, and all-cause death. Although 
the incidence of cardiovascular death tended to 
be higher in patients with MAC (log-rank, p = 
= 0.052), there were no significant differences in MI 
or all-cause death (log-rank, p = 0.468; p = 0.324, 
respectively). 
A Cox proportional hazards regression to 
evaluate the association of MAC with HFpEF 
rehospitalization is shown in Table 3. Univari-
ate regression demonstrated that age (hazard 
ratio [HR] 1.045; 95% confidence interval [CI] 
1.016–1.078; p = 0.002), hemoglobin (HR 0.787; 
95% CI 0.685–0.902; p = 0.001), LV end-diastolic 
dimension (HR 0.95; 95% CI 0.919–0.982; p = 
= 0.024), LV end-systolic dimension (HR 0.93; 95% 
CI 0.90–0.96; p < 0.001), and MAC (HR 4.016; 95% 
CI 2.005–7.643; p < 0.001) were significantly asso-
ciated with HFpEF rehospitalization. Multivariate 
Cox proportional hazard regression was performed 
to identify the association between MAC and 
HFpEF rehospitalization using three models: 
model 1, adjusted for age, gender, and hyperten-
sion; model 2, adjusted for age, hemoglobin, and LV 
end-diastolic dimension; and model 3, adjusted for 
age, hemoglobin, and LV end-systolic dimension. 
In all models, MAC remained significantly associ-
ated with HFpEF rehospitalization (all p < 0.05).
Discussion
In the current study, MAC was associated 
with an increased incidence of HF rehospitaliza-
tion, especially HFpEF rehospitalization. The 
multivariate analysis indicated that MAC might be 
a cause of HFpEF rehospitalization after adjusting 
for covariates.
Previous studies have reported that MAC is 
associated with CVD from various causes includ-
ing HF [6–8], and our study had a similar outcome. 
While studies have shown that MAC is a cause 
of HF, the etiology and mechanism of HF due to 
MAC has not been fully elucidated. The present 
study suggests a possible mechanism. In this study, 
MAC was especially associated with HFpEF re-
hospitalization. HFpEF is increasing in prevalence 
and is associated with substantial morbidity and 
mortality; however, limited treatments are avail-
able [18]. Myocardial hypertrophy and fibrosis [19], 
impaired diastolic compliance and relaxation [20], 
and elevated intracardiac filling pressures due to 
renal failure, fluid retention, and exercise intoler-
ance have been demonstrated to be complicatedly 
associated with the physiological mechanism of 
Figure 3. Kaplan-Meier estimates for secondary end-
points according to the presence or absence of mitral 
annulus calcification (MAC); A. All cause death; B. Car-















500 1000 1500 2000
Follow up (days)




























0 500 1000 1500 2000
Follow up (days)
































0 500 1000 1500 2000
Follow up (days)



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Yuta Kato et al., MAC and HF rehospitalization subtypes
HFpEF. In our study, patients with MAC had 
a higher E/e’ than those without MAC; moreover, 
they had a low e’ (septum and lateral) and a high 
LA volume index, suggesting that MAC may cause 
LV diastolic dysfunction. Certainly, it is difficult to 
distinguish that an increase in E/e’ occurs due to 
MAC or LV diastolic dysfunction. While previous 
studies have reported that patients with MAC 
had increased E velocities and decreased lateral 
e’ because of decreased mitral orifice and restric-
tion of posterior mitral leaflet excursion, little is 
known about the usefulness of septal e’ in those 
with MAC [21, 22]. In this study, both septal and 
lateral e’ were decreased. Our findings suggest that 
MAC might be a cause of HFpEF rehospitalization, 
along with older age, female sex, renal failure, 
anemia, hypertension, diabetes mellitus [15], and 
disturbed LV diastolic function. The mitral annu-
lus is located at the junction between the LV and 
LA. MAC might disturb the diastolic function of 
not only the LV but also the LA [23], resulting in 
increased rehospitalization due to HFpEF.
Although MAC is known as a chronic calcifica-
tion of the fibrous support structure of the mitral 
valve [1–3], the pathophysiological mechanism 
is not fully understood. Previously, the clinical 
causes of MAC were considered to be age-related 
calcification, atherosclerotic change, or CKD [2–5]. 
Regarding pathological findings, in specimens from 
patients with MAC, foam cells were observed on 
the ventricular surfaces of the posterior mitral 
leaflet, suggesting that MAC and atherosclerosis 
have a similar etiology [24]. On the other hand, 
the condition of mitral valve stress is increased in 
parallel with increased LV systolic pressure due 
to hypertension, aortic stenosis, and hypertrophic 
cardiomyopathy. The increased mitral valve stress 
contributes to increased mitral closing pressure, 
which accelerates degeneration of the mitral valve 
[25–27]. In addition, MAC was often observed in el-
derly females, and post-menopausal osteoporosis-
related ectopic calcium has been demonstrated to 
be deposited in the mitral valve [28, 29]. Because 
HFpEF rehospitalization occurred in 65% of the 
MAC group, these patients had characteristics of 
both HFpEF and MAC. There were no significant 
differences in creatinine between the groups be-
cause there were few CKD patients in this study.
Patients with symptomatic mitral valve dis-
ease who were intolerant to optimal medical 
therapy required invasive treatment. MAC affects 
the outcomes and strategies of open surgery (e.g. 
conversion from mitral valve repair to replace-
ment) [30, 31]. Furthermore, transcatheter edge-
to-edge mitral valve repair using a MitraClip® 
(Abbott Vascular Inc., Santa Clara, CA, USA) is 
contraindicated in MAC [30]. Surgical treatment 
for mitral valve disease with MAC requires calcium 
debridement, and consequently contributes to fatal 
cardiac complications such as atrioventricular dis-
ruption, LV free wall rupture, and injury of the left 
circumflex artery. On the other hand, Thaden et al. 
[32] reported that MAC was an independent pre-
dictor of an increased transmitral mean pressure 
gradient after transcatheter edge-to-edge mitral 
valve repair. Neither treatment might be suitable 
for patients with MAC. Several studies using 
a transcatheter aortic valve replacement device or 
a transcatheter mitral valve replacement device 
have been reported [33, 34]. Although both treat-
ments were feasible for patients who either were at 
high operative risk or were inoperable, they were 
still associated with significant cardiac adverse 
events, including all-cause death, cardiovascular 
death, and LV outflow tract obstruction. Proce-
dural experience, device refinements, and optimal 
patient selection are needed.
Limitations of the study
Our study has several limitations that should 
be considered. First, our study was a retrospective 
analysis performed at a single tertiary referral 
center with a limited number of study patients, and 
there was a potential selection bias. Furthermore, 
while the prevalence of MAC (11.3%) was similar 
to that in previous studies, the variables in the 
multivariate analysis were limited because of the 
small sample size. Second, while we investigated 
the patient characteristics, including basal car-
diomyopathy, comorbidities, society, medication 
at discharge, TTE findings, and biochemical data, 
we did not collect information on the triggers 
of acute decompensated HF such as afterload 
mismatch, infection, drug discontinuation, or 
medication at hospitalization. Third, because we 
divided patients with rehospitalization into three 
groups according to LVEF, we did not exclude 
cases of cardiomyopathy with preserved LVEF 
such as hypertrophic cardiomyopathy, restrictive 
cardiomyopathy, or amyloidosis. Thus, the rate of 
HFpEF rehospitalization might be affected by car-
diomyopathy with preserved LVEF besides MAC. 
Fourth, in our study, MAC was identified using 
echocardiography. However, it has been suggested 
that cardiac computed tomography is more useful 
than echocardiography because of its relatively low 
specificity in distinguishing between calcification 
and dense collagen [6, 35]. Most of the patients 
8 www.cardiologyjournal.org
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with MAC in the present study did not undergo 
cardiac computed tomography. Finally, the results 
of our study need further validation and evaluation 
in a larger prospective study.
Conclusions
In this study, MAC was associated with in-
creased HFpEF rehospitalization. It was sug-
gested that MAC might be a cause of LV diastolic 
dysfunction.
Acknowledgments 
The authors thank the patients, their families, 
and all investigators involved in this study.
Conflict of interest: Dr Miura reported receiv-
ing remunerations from Daiichi Sankyo Co. Ltd., 
Takeda Pharmaceutical Co. Ltd., Boehringer 
Ingelheim, Otsuka Pharmaceutical Co., and Bayer 
Yakuhin, Ltd., research funding from Daiichi 
Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., 
Astellas Pharma Inc., and Bayer Yakuhin, Ltd., and 
scholarship funds from Alfresa Corporation. The 
other authors report no conflicts.
References
1. Korn D, Desanctis RW, Sell S. Massive calcification of the mitral 
annulus. A clinicopathological study of fourteen cases. N Engl 
J Med. 1962; 267: 900–909, doi: 10.1056/NEJM196211012671802, 
indexed in Pubmed: 14034804.
2. Sell S, Scully RE. Aging changes in the aortic and mitral valves. 
Histologic and histochemical studies, with observations on the 
pathogenesis of calcific aortic stenosis and calcification of the 
mitral annulus. Am J Pathol. 1965; 46: 345–365, indexed in Pub-
med: 14270114.
3. Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral Annulus 
Calcification. J Am Coll Cardiol. 2015; 66(17): 1934–1941, doi: 
10.1016/j.jacc.2015.08.872, indexed in Pubmed: 26493666.
4. Kanjanauthai S, Nasir K, Katz R, et al. Relationships of mitral an-
nular calcification to cardiovascular risk factors: the Multi-Ethnic 
Study of Atherosclerosis (MESA). Atherosclerosis. 2010; 213(2): 
558–562, doi: 10.1016/j.atherosclerosis.2010.08.072, indexed in 
Pubmed: 20926076.
5. Adler Y, Fink N, Spector D, et al. Mitral annulus calcification: a win- 
dow to diffuse atherosclerosis of the vascular system. Athero-
sclerosis. 2001; 155(1): 1–8, doi: 10.1016/s0021-9150(00)00737-1.
6. Fox CS, Vasan RS, Parise H, et al. Mitral annular calcification 
predicts cardiovascular morbidity and mortality: the Framing-
ham Heart Study. Circulation. 2003; 107(11): 1492–1496, doi: 
10.1161/01.cir.0000058168.26163.bc, indexed in Pubmed: 
12654605.
7. Nair CK, Thomson W, Ryschon K, et al. Long-term follow-up 
of patients with echocardiographically detected mitral anular 
calcium and comparison with age- and sex-matched control sub-
jects. Am J Cardiol. 1989; 63(7): 465–470, doi: 10.1016/0002-
9149(89)90321-4, indexed in Pubmed: 2916432.
8. Mellino M, Salcedo EE, Lever HM, et al. Echographic-quantified 
severity of mitral anulus calcification: prognostic correlation to 
related hemodynamic, valvular, rhythm, and conduction abnor-
malities. Am Heart J. 1982; 103(2): 222–225, doi: 10.1016/0002-
8703(82)90495-1, indexed in Pubmed: 7055055.
9. Fulkerson PK, Beaver BM, Auseon JC, et al. Calcification of the 
mitral annulus: etiology, clinical associations, complications and 
therapy. Am J Med. 1979; 66(6): 967–977, doi: 10.1016/0002-
9343(79)90452-2, indexed in Pubmed: 156499.
10. Kizer JR, Wiebers DO, Whisnant JP, et al. Mitral annular cal-
cification, aortic valve sclerosis, and incident stroke in adults 
free of clinical cardiovascular disease: the Strong Heart 
Study. Stroke. 2005; 36(12): 2533–2537, doi: 10.1161/01.
STR.0000190005.09442.ad, indexed in Pubmed: 16254219.
11. Benjamin EJ, Plehn JF, D’Agostino RB, et al. Mitral annular calci-
fication and the risk of stroke in an elderly cohort. N Engl J Med. 
1992; 327(6): 374–379, doi: 10.1056/NEJM199208063270602, 
indexed in Pubmed: 1625711.
12. Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure. 
Eur J Heart Fail. 2016; 18(8): 891–975, doi: 10.1002/ejhf.592.
13. Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart 
failure patients with mid-range left ventricular ejection fraction 
a report from the CHART-2 Study. Eur J Heart Fail. 2017; 19(10): 
1258–1269, doi: 10.1002/ejhf.807, indexed in Pubmed: 28370829.
14. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence 
and outcome of heart failure with preserved ejection fraction. 
N Engl J Med. 2006; 355(3): 251–259, doi: 10.1056/NEJ-
Moa052256, indexed in Pubmed: 16855265.
15. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with 
preserved ejection fraction in a population-based study. N Engl 
J Med. 2006; 355(3): 260–269, doi: 10.1056/NEJMoa051530, in-
dexed in Pubmed: 16855266.
16. McKee PA, Castelli WP, McNamara PM, et al. The natural history 
of congestive heart failure: the Framingham study. N Engl J Med. 
1971; 285(26): 1441–1446, doi: 10.1056/NEJM197112232852601, 
indexed in Pubmed: 5122894.
17. Kohsaka S, Jin Z, Rundek T, et al. Impact of mitral annular cal-
cification on cardiovascular events in a multiethnic community: 
the Northern Manhattan Study. JACC Cardiovasc Imaging. 2008; 
1(5): 617–623, doi: 10.1016/j.jcmg.2008.07.006, indexed in Pub-
med: 19356491.
18. Redfield MM. Heart Failure with Preserved Ejection Fraction. 
N Engl J Med. 2017; 376(9): 896–897, doi: 10.1056/nejmc1615918.
19. Mohammed SF, Hussain S, Mirzoyev SA, et al. Coronary micro-
vascular rarefaction and myocardial fibrosis in heart failure with 
preserved ejection fraction. Circulation. 2015; 131(6): 550–559, 
doi: 10.1161/CIRCULATIONAHA.114.009625, indexed in Pub-
med: 25552356.
20. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnor-
malities in active relaxation and passive stiffness of the left 
ventricle. N Engl J Med. 2004; 350(19): 1953–1959, doi: 10.1056/
NEJMoa032566, indexed in Pubmed: 15128895.
21. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations 
for the Evaluation of Left Ventricular Diastolic Function by Echo-
cardiography: An Update from the American Society of Echocar-
diography and the European Association of Cardiovascular Imag-
ing. J Am Soc Echocardiogr. 2016; 29(4): 277–314, doi: 10.1016/j.
echo.2016.01.011, indexed in Pubmed: 27037982.
www.cardiologyjournal.org 9
Yuta Kato et al., MAC and HF rehospitalization subtypes
22. Soeki T, Fukuda N, Shinohara H, et al. Mitral inflow and mitral 
annular motion velocities in patients with mitral annular calcifica-
tion: evaluation by pulsed Doppler echocardiography and pulsed 
Doppler tissue imaging. Eur J Echocardiogr. 2002; 3(2): 128–134, 
doi: 10.1053/euje.2001.0137, indexed in Pubmed: 12114097.
23. Bayramoğlu A, Taşolar H, Otlu YÖ, et al. Assessment of left 
atrial volume and mechanical functions using real-time three-
dimensional echocardiography in patients with mitral annular 
calcification. Anatol J Cardiol. 2016; 16(1): 42–47, doi: 10.5152/
akd.2015.5897, indexed in Pubmed: 26467362.
24. Roberts W. The senile cardiac calcification syndrome. Am J Car-
diol. 1986; 58(6): 572–574, doi: 10.1016/0002-9149(86)90045-7.
25. Nestico PF, Depace NL, Morganroth J, et al. Mitral annular calci-
fication: clinical, pathophysiology, and echocardiographic review. 
Am Heart J. 1984; 107(5 Pt 1): 989–996, doi: 10.1016/0002-
8703(84)90840-8, indexed in Pubmed: 6372421.
26. Roberts WC, Perloff JK. Mitral valvular disease. A clinicopatho-
logic survey of the conditions causing the mitral valve to func-
tion abnormally. Ann Intern Med. 1972; 77(6): 939–975, doi: 
10.7326/0003-4819-77-6-939, indexed in Pubmed: 4566285.
27. Silbiger JJ. Anatomy, mechanics, and pathophysiology of the mi-
tral annulus. Am Heart J. 2012; 164(2): 163–176, doi: 10.1016/j.
ahj.2012.05.014, indexed in Pubmed: 22877801.
28. Roberts W. Morphologic features of the normal and abnormal 
mitral valve. Am J Cardiol. 1983; 51(6): 1005–1028, doi: 10.1016/
s0002-9149(83)80181-7.
29. Sugihara N, Matsuzaki M. The influence of severe bone loss 
on mitral annular calcification in postmenopausal osteoporosis 
of elderly Japanese women. Jpn Circ J. 1993; 57(1): 14–26, doi: 
10.1253/jcj.57.14, indexed in Pubmed: 8437338.
30. Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve dis-
ease--current management and future challenges. Lancet. 2016; 
387(10025): 1324–1334, doi: 10.1016/S0140-6736(16)00558-4, 
indexed in Pubmed: 27025438.
31. Fusini L, Ghulam Ali S, Tamborini G, et al. Prevalence of calcifi-
cation of the mitral valve annulus in patients undergoing surgical 
repair of mitral valve prolapse. Am J Cardiol. 2014; 113(11): 
1867–1873, doi: 10.1016/j.amjcard.2014.03.013, indexed in Pub-
med: 24837266.
32. Thaden JJ, Malouf JF, Nkomo VT, et al. Mitral valve anatomic pre-
dictors of hemodynamic success with transcatheter mitral valve 
repair. J Am Heart Assoc. 2018; 7(2): e007315, doi: 10.1161/
JAHA.117.007315, indexed in Pubmed: 29331957.
33. Guerrero M, Dvir D, Himbert D, et al. Transcatheter mitral 
valve replacement in Native Mitral valve disease with severe mi-
tral annular calcification: results from the first multicenter global 
registry. JACC Cardiovasc Interv. 2016; 9(13): 1361–1371, doi: 
10.1016/j.jcin.2016.04.022, indexed in Pubmed: 27388824.
34. Sorajja P, Gössl M, Babaliaros V, et al. Novel transcatheter mitral 
valve prosthesis for patients with severe mitral annular calcifica-
tion. J Am Coll Cardiol. 2019; 74(11): 1431–1440, doi: 10.1016/j.
jacc.2019.07.069, indexed in Pubmed: 31514943.
35. Higgins J, Mayo J, Skarsgard P. Cardiac computed tomography 
facilitates operative planning in patients with mitral calcification. 
Ann Thorac Surg. 2013; 95(1): e9–11, doi: 10.1016/j.athorac-
sur.2012.07.059, indexed in Pubmed: 23272892.
10 www.cardiologyjournal.org
Cardiology Journal
